AGCO Agriculture Foundation and MANRRS Announce a Three-Year Partnership to Advance Minority Representation in the Agricultural Industry
The AGCO Agriculture Foundation (AAF), a private foundation committed to ending hunger through sustainable agricultural development, today announced a three-year partnership with Minorities in Agriculture, Natural Resources, and Related Sciences (MANRRS) to increase student representation from underrepresented backgrounds and to promote the agriculture industry as an admirable and sound career choice.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005271/en/
AGCO Agriculture Foundation announces partnership with MANRRS (Graphic: Business Wire)
Funded by the AAF, the project will provide scholarship opportunities for tailored internship roles and support for hiring talent from underrepresented groups. The focus areas will be agronomy, agribusiness, engineering, data science, software development, sustainability, field technicians, and related disciplines. The goal is to increase diversity and promote the agricultural industry as a viable career.
“AGCO Agriculture Foundation is committed to working to address the diversity gap in the U.S. agricultural industry,” said Metti Richenhagen, Director, AGCO Agriculture Foundation. “Our partnership with MANRRS enables a diverse group of young agricultural enthusiasts to gain knowledge, skills, and professional experience within high-demand areas of our industry.”
The scholarship program will launch in late 2021, with internship commitments for the summer of 2022. In each of the next three years, the AAF will award 16 scholarships to selected minority students in the United States and, together with AGCO Corporation, will create a development and growth program for interns that will serve as a multi-year pathway to help minority students develop competencies and capabilities that align with post-collegiate career opportunities.
“Solving farmers’ most pressing challenges requires continuous innovation and diverse thinking. The AAF partnership with MANRRS enhances our ability to innovate for farmers by building a more diverse talent pipeline. We are thrilled to be able to offer these talented students development opportunities at AGCO,” said Eric Haggard, Director, Global Diversity, Equity and Inclusion at AGCO Corporation.
The program will be advertised and available at Historically Black Colleges and Universities (HBCUs) and other minority-serving institutions. The scholarships will also include invitations for the 16 selected students to participate in the MANRRS 36th Annual Training Conference and Career Expo. Across the United States, MANRRS has a database of over 8,000 members and 55 university and college chapters in 39 states.
“MANRRS is excited about this new program. Our funding support and partnership with the AAF will help more exceptional talents within our network develop their leadership skills while contributing to the transformation of the agri-food industry. To develop state-of-the-art innovation and make strides towards zero hunger, the agricultural industry must be well-positioned to attract diverse talent like our MANRRS members,” said Ebony Webber, Chief Officer of Operations, MANRRS National Office.
About the AGCO Agriculture Foundation (AAF)
The AGCO Agriculture Foundation (AAF), initiated by AGCO Corporation (NYSE: AGCO) in 2018, is a private foundation with the vision to prevent and relieve hunger. The foundation initiates impactful programs that support food security, foster sustainable agricultural development and build needed agricultural infrastructure in marginalized farming communities. AAF is domiciled in Vaduz, Liechtenstein and operations are managed from Duluth, Georgia, USA. For more information, please visit https://www.agcofoundation.org/
About MANRRS
MANRRS is a non-profit organization registered in the state of Michigan. MANRRS is a national society that welcomes membership of people of all racial and ethnic group participation in agricultural and related science careers. MANRRS attempts to provide networks to support professional development of minorities. It is a springboard for their entry into and advancement in careers where they otherwise could be lost in the sheer number and established connections of mainstream participants. For more information visit the national website www.manrrs.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005271/en/
Contact information
Press contact
Metti Richenhagen, AGCO Agriculture Foundation
metti.richenhagen@agcocorp.com
Ebony Webber, MANRRS National Office
ebony.webber@MANRRS.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom